A clinic at Fred Hutch addresses sexual health needs of patients with breast cancerData indicate low adherence to ASCO guideline November 15, 2024Vol.50 No.43By Claire Marie Porter
Trials & Tribulations How we improved the treatment of Hodgkin lymphoma November 15, 2024Vol.50 No.43By Alex Herrera
Trials & Tribulations A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment November 08, 2024Vol.50 No.42By Otis W. Brawley
Trials & Tribulations Addressing high cancer mortality in Native Hawaiian and Pacific Islander populationsA call for equity in cancer research November 01, 2024Vol.50 No.41By Naoto T. Ueno
GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation October 25, 2024Vol.50 No.40By Jacquelyn Cobb
NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials October 25, 2024Vol.50 No.40By Claire Marie Porter
Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo October 18, 2024Vol.50 No.39By McKenzie Prillaman
Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer October 18, 2024Vol.50 No.39By Jacquelyn Cobb
Trials & Tribulations Cancer clinical trials shouldn’t discriminate—but they do October 11, 2024Vol.50 No.38By Erin Miller
Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies September 13, 2024Vol.50 No.34By McKenzie Prillaman
